RIA
VRTX icon

Regal Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Regal Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Buy
3,238
+655
+25% +$290K 0.08% 239
2026
Q1 		$1.15M Buy
2,583
+43
+2% +$20.1K 0.07% 266
2025
Q4 		$1.15M Buy
2,540
+97
+4% +$41.8K 0.07% 253
2025
Q3 		$957K Buy
2,443
+272
+13% +$114K 0.06% 270
2025
Q2 		$966K Buy
2,171
+366
+20% +$169K 0.07% 242
2025
Q1 		$875K Buy
1,805
+4
+0.2% +$1.86K 0.07% 239
2024
Q4 		$725K Sell
1,801
-177
-9% -$82K 0.05% 270
2024
Q3 		$920K Sell
1,978
-78
-4% -$37.5K 0.06% 253
2024
Q2 		$963K Buy
2,056
+73
+4% +$31.7K 0.06% 257
2024
Q1 		$829K Buy
1,983
+51
+3% +$21.6K 0.06% 270
2023
Q4 		$786K Buy
1,932
+797
+70% +$294K 0.06% 257
2023
Q3 		$395K Sell
1,135
-27
-2% -$9.44K 0.03% 337
2023
Q2 		$409K Buy
1,162
+145
+14% +$48.9K 0.03% 329
2023
Q1 		$320K Sell
1,017
-3,970
-80% -$1.19M 0.03% 373
2022
Q4 		$1.44M Sell
4,987
-704
-12% -$215K 0.14% 151
2022
Q3 		$1.65M Buy
5,691
+462
+9% +$133K 0.17% 134
2022
Q2 		$1.47M Buy
5,229
+2,268
+77% +$607K 0.15% 138
2022
Q1 		$773K Buy
2,961
+1,083
+58% +$257K 0.07% 251
2021
Q4 		$412K Buy
1,878
+17
+0.9% +$3.31K 0.04% 362
2021
Q3 		$338K Buy
1,861
+172
+10% +$33.6K 0.03% 395
2021
Q2 		$341K Buy
+1,689
New +$353K 0.03% 384
2021
Q1 		– Sell
-1,051
Closed -$248K – 422
2020
Q4 		$248K Buy
+1,051
New +$241K 0.03% 401
2020
Q3 		– Sell
-1,279
Closed -$371K – 294
2020
Q2 		$371K Buy
+1,279
New +$347K 0.07% 210
2020
Q1 		– Sell
-1,602
Closed -$351K – 305
2019
Q4 		$351K Buy
+1,602
New +$324K 0.06% 244

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Regal Investment Advisors's VRTX Position: Q2 2026 in Review

Regal Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 25% in Q2 2026, buying an estimated $290K and bringing the position to 3,238 shares worth $1.61M. The position accounts for 0.08% of the portfolio, ranked #239.

Regal Investment Advisors first reported a position in VRTX in Q4 2019 and has held it in 24 quarters since. The position peaked at $1.65M in Q3 2022. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Regal Investment Advisors held 3,238 shares of Vertex Pharmaceuticals worth $1.61M as of Q2 2026.
  • Regal Investment Advisors bought 655 Vertex Pharmaceuticals shares in Q2 2026, an estimated $290K.
  • Vertex Pharmaceuticals made up 0.08% of Regal Investment Advisors's portfolio in Q2 2026, its #239 holding.
  • Regal Investment Advisors first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 24 quarters since.
  • Regal Investment Advisors's Vertex Pharmaceuticals position peaked at $1.65M in Q3 2022.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Regal Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.